China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
CAMBRIDGE, Mass., Oct. 03, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in New York in October. Details are as follows:
Chardan Gene Therapy Conference
Tuesday, October 10
- Manufacturing Panel | 12:15 p.m. ET
- Fireside Chat | 3:45 p.m. ET
Jefferies Gene Technology Investor Summit
Thursday, October 12
- Presentation | 1:20 p.m. ET
A live webcast of the events will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the events.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact
Cristi Barnett
Editas Medicine, Inc.
(617) 401-0113
[email protected]
Investor Contact
Mark Mullikin
Editas Medicine, Inc.
(617) 401-9083
[email protected]
